Many methods to measure pharmacodynamic endpoints are currently available, for instance, enzyme-linked immunosorbent assay (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and western blotting. Measuring these endpoints is a crucial step in optimizing your compound to transition into clinical trials. However, when it comes to sensitivity, accuracy, and economic efficiency, Meso Scale Discovery (MSD) biomarker assays prove to be an advantageous option to further develop your compound. The platform comprises of different assay kits that allow rapid measurement of the levels of a specific biomarker within a single, small-volume sample.
How it works:
The MSD technology leverages electrochemiluminescence technology through parallel processing of biological assays and provides a quantitative measure of the analyte with your sample. There are over 500 assay panels, custom panels, and reagent kits enabling for a large variety of protein analyses. You can view the whole list of available MSD assays here
If your analyte is not already validated within one of the available kits, InnoSer can provide you with the expertise coupled with validation services enabling you to assess your specific analyte. By introducing biomarker discovery early on in your research through this customizable approach you will increase the translational power of your preclinical research.
Benefits:
With MSD’s novel technology, we now have the capabilities to provide greater sensitivity, precision, reproducibility, and absolute quantification. These added benefits come with faster turnaround times for your results and lower costs than traditional methods like ELISA or Western Blot due to its multiplex system that allows an analysis of up to 10 markers in a single well.
With a wide range of applications, this analysis technique can be applied to many different study types adding value and saving time to a range of projects. The ready to use validated panels include:
- Cytokines & Chemokines
- Oncology
- Angiogenesis & Vascular analytes
- Bone Metabolism
- Cardiovascular
- Metabolism
- Inflammation
- Intracellular Signaling
- Neurodegeneration
- Toxicology
- GPCR-ligand binding proteins
- Immunology
- Growth factors
- Hypoxia
Through thorough preclinical investigation, we can increase the translatability of your lead compounds from the preclinical stage into clinical trials. Using a variety of techniques combined with the most appropriate readouts, InnoSer will work closely with you in providing expertise at every step of your drug development process.
Do you have more questions about how MSD technology could benefit your research?
Want to read more?
InnoSer and Inficure Bio enter partnership to increase accessibility of translational liver inflammation & fibrosis mouse model
October 27th Diepenbeek, Belgium and Umeà, Sweden - InnoSer and Inficure Bio are announcing a strategic partnership to offer Inficure Bio’s spontaneous liver inflammation & fibrosis mouse model (NIF mouse) as part of InnoSer’s expanding cardiometabolic...
InnoSer expands preclinical cancer readout capabilities through acquisition of new imagers.
Getting closer to understanding cancer through the adoption of technological advancements is crucial in providing deeper insights for our customers. By building robust and reliable dossiers for promising drug candidates moving into clinical trials, we can help our...
Discussing innovation and the PDX/O platform at SINERGIA Summer School
We strive to stay at the forefront of biotechnological developments and to constantly incorporate innovation in our offerings - this is essential to be able to develop more reliable drug development platforms and avoid high drug attrition rates. Study director...